Kantaro Biosciences, LLC , a joint venture between Mount Sinai Health System and Renalytix AI plc , expects its SARS-CoV-2 IgG antibody test kit will allow researchers and public health officials to track the effectiveness of the COVID-19 vaccination programs that will likely begin soon.
“We're approaching a tipping point in the pandemic … where we're going to be moving into a very significant need...